12.99
0.36 (2.85%)
| Previous Close | 12.63 |
| Open | 12.62 |
| Volume | 202,862 |
| Avg. Volume (3M) | 220,329 |
| Market Cap | 474,517,536 |
| Price / Sales | 11.15 |
| Price / Book | 1.74 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Diluted EPS (TTM) | -2.49 |
| Total Debt/Equity (MRQ) | 3.25% |
| Current Ratio (MRQ) | 21.47 |
| Operating Cash Flow (TTM) | -39.28 M |
| Levered Free Cash Flow (TTM) | -26.34 M |
| Return on Assets (TTM) | -22.95% |
| Return on Equity (TTM) | -33.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Contineum Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.13 |
|
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.82% |
| % Held by Institutions | 79.99% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (Baird, 53.97%) | Buy |
| Median | 17.00 (30.87%) | |
| Low | 14.00 (Morgan Stanley, 7.78%) | Hold |
| Average | 17.00 (30.87%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 11.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 06 Mar 2026 | 20.00 (53.96%) | Buy | 13.88 |
| Morgan Stanley | 08 Jan 2026 | 14.00 (7.78%) | Hold | 9.17 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |